(Q53938789)

English

Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

stem cell transplantation

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

author name string

Terpos E

1

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Apperley JF

2

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Samson D

3

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Giles C

4

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Crawley C

5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Kanfer E

6

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Olavarria E

7

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Goldman JM

8

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Rahemtulla A

9

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

language of work or name

0 references

publication date

1 February 2003

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

31

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

3

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

163-170

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Long-term follow-up after high-dose therapy for high-risk multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Non-secretory multiple myeloma: a report of 13 cases with a review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

21 January 2018

Diagnosis and management of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of complete response on outcome following autologous stem cell transplantation for myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703818

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1703818

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/12621476

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53938789&oldid=2212327151"